OncoCyte Overview
- Founded
-
2009
- Status
-
Public
- Employees
-
115
- Stock Symbol
-
OCX
- Investments
-
5
- Share Price
-
$0.98
- (As of Thursday Closing)
OncoCyte General Information
Description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Contact Information
Primary Industry
Diagnostic Equipment
Other Industries
Discovery Tools (Healthcare)
Stock Exchange
NAS
Primary Office
- 15 Cushing
- Irvine, CA 92618
- United States
+1 (949) 000-0000
OncoCyte Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.98 | $0.95 | $0.81 - $5.48 | $119M | 125M | 474K | -$0.72 |
OncoCyte Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 90,761 | 162,105 | 158,526 | 109,684 |
| Revenue | 8,064 | 7,727 | 1,216 | 0 |
| EBITDA | (63,182) | (68,944) | (30,540) | (22,374) |
| Net Income | (68,276) | (64,097) | (29,932) | (22,426) |
| Total Assets | 171,051 | 159,563 | 55,419 | 39,859 |
| Total Debt | 4,547 | 5,677 | 8,632 | 5,936 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
OncoCyte Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
OncoCyte Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnos
Diagnostic Equipment
Irvine, CA
115
As of 2021
000.00
000000000
000.00
000000
uis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure do
0000000000000
San Diego, CA
000
As of 0000
00000
000000000
00000
000000
abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000000000 000000000
Redwood City, CA
0000
As of 0000
00000
000000 - 000
00000
Add Comparison
OncoCyte Competitors (34)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| DermTech | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 | 00000 |
| 00000000 000000 | Formerly VC-backed | Redwood City, CA | 0000 | 00000 | 000000 - 000 | 00000 |
| 0000000 | Formerly VC-backed | Cambridge, United Kingdom | 00 | 00000 | 000000&0 | 00000 |
| 000000000 | Venture Capital-Backed | Siena, Italy | 00 | 0000000000 0 | ||
| 00000000 | Venture Capital-Backed | Seattle, WA | 00 | 0000 | 00000000000 | 0000 |
OncoCyte Patents
OncoCyte Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20130295581-A1 | Methods and compositions for the treatment and diagnosis of breast cancer | Abandoned | 04-May-2012 | 00000000000 | 0 |
| US-20150018235-A1 | Methods and compositions for the treatment and diagnosis of pancreatic cancer | Abandoned | 13-Jan-2012 | 000000000000 | |
| US-20140357518-A1 | Methods and compositions for the treatment and diagnosis of thyroid cancer | Abandoned | 12-Jan-2012 | 0000000000 | |
| AU-2012203810-B2 | Methods and compositions for the treatment and diagnosis of bladder cancer | Ceased | 22-Jun-2011 | 0000000000 | 0 |
| EP-2723898-A4 | Methods and compositions for the treatment and diagnosis of bladder cancer | Withdrawn | 22-Jun-2011 | C12Q1/6886 | 0 |
OncoCyte Executive Team (12)
OncoCyte Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alfred Kingsley JD | Self | Board Member | 000 0000 |
| Andrew Arno | OncoCyte | Chairman & Board Member | 000 0000 |
| Andrew Last Ph.D | Self | Board Member | 000 0000 |
| Jennifer Carter MD | Self | Board Member | 000 0000 |
| Melinda Griffith JD | Self | Board Member | 000 0000 |
OncoCyte Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
OncoCyte Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
OncoCyte Investments & Acquisitions (5)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 00000 | 19-Apr-2021 | 0000000000 | 000.00 | Laboratory Services (Healthcare) | 000000 00 |
| 00000 0000000 | 25-Feb-2021 | 0000000000 | 0000 | Diagnostic Equipment | 000000 00 |
| 0000000 00000 | 31-Jan-2020 | 0000000000 | 0000 | Biotechnology | 000000 00 |
| 00000 0000000 | 05-Sep-2019 | 000000000 | 0000 | Diagnostic Equipment | 00000000 |
| Cell Targeting | 28-Jan-2011 | Merger/Acquisition | 00.00 | Biotechnology |
OncoCyte Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Razor Genomics | Diagnostic Equipment | Brisbane, CA | 2014 |
| 0000000 00000000 | Biotechnology | Nashville, TN | 0000 |